Another strong quarter, another outlook upgrade but challenges don’t abate
16/08/17 -"Novo Nordisk reported yet another better-than-expected quarter. Q2 sales of DKK28.6bn (+3% in LC; +4% in DKK) were close to our estimate of DKK28.4bn, but the operating profit margin of 46.7% came as ..."
Pages
74
Language
English
Published on
16/08/17
You may also be interested by these reports :
03/05/24
Genmab’s Q1 sales exceeded expectations, although profitability fell somewhat short. This robust performance was led by strong growth across all the ...
03/05/24
We have rolled forward our model to include a new forecast year (2026) which will also see continued healthy top-line growth and profitability ...
02/05/24
CureVac did not really tidy things up. The cost-cutting measures, as presented, are insufficient and do not meet our ideal scenario of a focused and ...
02/05/24
The Q1 results exceeded the street’s expectations, driven by the strong momentum for Novo’s diabetes and obesity offerings. While the management ...